Oncolytics Biotech (TSE:ONC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolytics Biotech reported positive results for its pelareorep and paclitaxel combination, showing significant improvements in survival rates for metastatic breast cancer patients. The company, with a solid cash position, plans to advance to a registration-enabling study. Oncolytics’ financial stability and promising clinical data suggest potential growth in the oncology sector.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.